Literature DB >> 24234650

Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia.

Ana Catarina Alves1, Aitor Etxebarria, Anne Katherine Soutar, Cesar Martin, Mafalda Bourbon.   

Abstract

Familial hypercholesterolaemia (FH) is characterized by increased circulating low-density lipoprotein (LDL) cholesterol leading to premature atherosclerosis and coronary heart disease. Although FH is usually caused by mutations in LDLR, mutations in APOB and PCSK9 also cause FH but only a few mutations have been reported, APOB p.R3527Q being the most common. However, 30-80% of clinical FH patients do not present an identifiable mutation in any of the described genes. To identify the genetic cause of the hypercholesterolaemia in 65 patients without mutations in LDLR, PCSK9 or in fragments of exon 26 and 29 of APOB currently analysed, we performed whole sequencing of APOB by pyrosequencing. A total of 10 putative mutations in APOB were identified. Flow cytometry with fluorescently labelled LDL from patients and relatives showed that p.Arg1164Thr (exon 22) and p.Gln4494del (exon 29) presented a 40% decrease in internalization in lymphocytes and HepG2 cells, very similar to APOB3527. The proliferation assays with U937 cells showed reduced growth for both cases. The variant p.Tyr1247Cys was found to be neutral and other three alterations were considered polymorphisms. Our results emphasize the need to study the whole APOB in routine protocols to improve patient identification and cardiovascular risk assessment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24234650     DOI: 10.1093/hmg/ddt573

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

1.  ClinVar database of global familial hypercholesterolemia-associated DNA variants.

Authors:  Michael A Iacocca; Joana R Chora; Alain Carrié; Tomáš Freiberger; Sarah E Leigh; Joep C Defesche; C Lisa Kurtz; Marina T DiStefano; Raul D Santos; Steve E Humphries; Pedro Mata; Cinthia E Jannes; Amanda J Hooper; Katherine A Wilemon; Pascale Benlian; Robert O'Connor; John Garcia; Hannah Wand; Lukáš Tichy; Eric J Sijbrands; Robert A Hegele; Mafalda Bourbon; Joshua W Knowles
Journal:  Hum Mutat       Date:  2018-11       Impact factor: 4.878

2.  Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.

Authors:  René Wintjens; Dominique Bozon; Khaldia Belabbas; Félicien MBou; Jean-Philippe Girardet; Patrick Tounian; Mathilde Jolly; Franck Boccara; Ariel Cohen; Alexandra Karsenty; Béatrice Dubern; Jean-Claude Carel; Ahlam Azar-Kolakez; François Feillet; François Labarthe; Anne-Marie Colin Gorsky; Alice Horovitz; Catherine Tamarindi; Pierre Kieffer; Anne Lienhardt; Olivier Lascols; Mathilde Di Filippo; Fabienne Dufernez
Journal:  J Lipid Res       Date:  2016-01-22       Impact factor: 5.922

3.  Role of Rare and Low-Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels.

Authors:  Zhe Wang; Han Chen; Traci M Bartz; Lawrence F Bielak; Daniel I Chasman; Mary F Feitosa; Nora Franceschini; Xiuqing Guo; Elise Lim; Raymond Noordam; Melissa A Richard; Heming Wang; Brian Cade; L Adrienne Cupples; Paul S de Vries; Franco Giulanini; Jiwon Lee; Rozenn N Lemaitre; Lisa W Martin; Alex P Reiner; Stephen S Rich; Pamela J Schreiner; Stephen Sidney; Colleen M Sitlani; Jennifer A Smith; Ko Willems van Dijk; Jie Yao; Wei Zhao; Myriam Fornage; Sharon L R Kardia; Charles Kooperberg; Ching-Ti Liu; Dennis O Mook-Kanamori; Michael A Province; Bruce M Psaty; Susan Redline; Paul M Ridker; Jerome I Rotter; Eric Boerwinkle; Alanna C Morrison
Journal:  Circ Genom Precis Med       Date:  2020-06-08

Review 4.  Familial Hypercholesterolaemia in the Era of Genetic Testing.

Authors:  D P Hughes; A Viljoen; A S Wierzbicki
Journal:  Curr Cardiol Rep       Date:  2016-05       Impact factor: 2.931

5.  Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.

Authors:  Abhimanyu Garg; Sergio Fazio; P Barton Duell; Alexis Baass; Chandrasekhar Udata; Tenshang Joh; Tom Riel; Marina Sirota; Danielle Dettling; Hong Liang; Pamela D Garzone; Barry Gumbiner; Hong Wan
Journal:  J Endocr Soc       Date:  2019-11-29

6.  Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement.

Authors:  Ana Margarida Medeiros; Ana Catarina Alves; Mafalda Bourbon
Journal:  Genet Med       Date:  2015-05-28       Impact factor: 8.822

7.  Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.

Authors:  Eduardo Vilar-Gomez; Samer Gawrieh; Tiebing Liang; Adam D McIntyre; Robert A Hegele; Naga Chalasani
Journal:  J Clin Lipidol       Date:  2020-12-27       Impact factor: 4.766

Review 8.  Complement and macrophage crosstalk during process of angiogenesis in tumor progression.

Authors:  M Afzal Khan; A M Assiri; D C Broering
Journal:  J Biomed Sci       Date:  2015-07-22       Impact factor: 8.410

9.  Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis.

Authors:  Joana Rita Chora; Ana Margarida Medeiros; Ana Catarina Alves; Mafalda Bourbon
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

10.  Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.

Authors:  Ilze Radovica-Spalvina; Gustavs Latkovskis; Ivars Silamikelis; Davids Fridmanis; Ilze Elbere; Karlis Ventins; Guna Ozola; Andrejs Erglis; Janis Klovins
Journal:  BMC Med Genet       Date:  2015-09-28       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.